- Easy-to-use - ready-to-use liquid color-coded reagents reduce errors
- Higher throughput - reproducible results from up to 39 samples in duplicate in just 3 hours
- Trusted - validated with pathological and non-pathological samples
The Dkk-1 (human), EIA kit is a colorimetric immunometric enzyme immunoassay kit with results in 3 hours. Absorbance is read at 450 nm. The Dkk-1 (human), EIA kit offers ultra-sensitive and accurate measurement of Dickkopf-1 and has been validated in-house in normal and pathological samples.
Please mouse over
Product Details
| Alternative Name: | Dickkopf-1 |
| |
| Sensitivity: | 0.98 pg/ml (range 7.81-500 pg/ml) |
| |
| Assay Time: | 3 hours |
| |
| Applications: | ELISA, Colorimetric detection
|
| |
| Application Notes: | For the quantitative determination of human Dkk-1 in culture supernatants, plasma, and serum. |
| |
| Wavelength: | 450 nm |
| |
| Species reactivity: | Human
|
| |
| Use/Stability: | Store all components at 4°C, except standard at -20°C. |
| |
| Shipping: | Shipped on Blue Ice |
| |
| Contents: | Microtiter plate, Conjugate, Antibody, Assay buffer 10 Concnetrate, Wash buffer concentrate, Standard, TMB Substrate, Stop solution 2 |
| |
| Scientific Background: | Dkk-1 (Dickkopf-1) is a secreted inhibitor of the canonical Wnt signaling pathway, which mediates a variety of cellular processes including the growth and development of osteoblasts. Dkk-1 disrupts the canonical pathway by binding to the LRP5/6 co-receptors, preventing interaction with Wnt, and facilitating the degradation of beta-catenin. Dkk-1 is overexpressed in multiple myeloma, increasing bone resorption and the appearance of osteolytic lesions characteristic of multiple myeloma. |
| |
| UniProt ID: | O94907 |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
| Compatibility: | This product is compatible with the Absorbance 96 Plate Reader.
 |
| |
Product Literature References
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma: M. Delforge, et al.; Eur. J. Haematol.
86, 372 (2011),
Application(s): EIA using human serum,
Abstract;
Lack of diagnostic potential of Dickkopf-1 in colon and rectum cancers: H.O. Soydinc, et al.; Asian Pac. J. Cancer. Prev.
12, 3187 (2011),
Application(s): EIA using human serum,
Abstract;
Full Text
The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis: A.M. Betts, et al.; J. Pharmacol. Exp. Ther.
333, 2 (2010),
Application(s): EIA using human serum,
Abstract;
Full Text
Related Products
